Episode
Live From WCLC 2026: Monday Highlights
- Podcast
- Lung Cancer Considered
- Published
- Sep 14, 2026
- Duration seconds
- 1878
- Processing state
not_requested- Audio
- https://feeds.soundcloud.com/stream/2400727197-lungcancerconsidered-live-from-wclc-2026-monday.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-considered-246259/episodes/live-from-wclc-2026-monday-highlights/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-considered-246259/live-from-wclc-2026-monday-highlights.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday. A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Attending Physician, Thoracic Oncology Service Giannis Mountzios, MD, MSc, PhD Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit Henry Dunant Hospital Center Athens, Greece,